NO975953L - Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene - Google Patents

Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene

Info

Publication number
NO975953L
NO975953L NO975953A NO975953A NO975953L NO 975953 L NO975953 L NO 975953L NO 975953 A NO975953 A NO 975953A NO 975953 A NO975953 A NO 975953A NO 975953 L NO975953 L NO 975953L
Authority
NO
Norway
Prior art keywords
adenoviruses
aavs
preparation
cell line
pharmaceutical preparations
Prior art date
Application number
NO975953A
Other languages
English (en)
Norwegian (no)
Other versions
NO975953D0 (no
Inventor
Martine Latta
Cecile Orsini
Michel Perricaudet
Edouard Proust
Emmanuelle Vigne
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO975953D0 publication Critical patent/NO975953D0/no
Publication of NO975953L publication Critical patent/NO975953L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO975953A 1995-06-23 1997-12-18 Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene NO975953L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9507570A FR2735789B1 (fr) 1995-06-23 1995-06-23 Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
PCT/FR1996/000968 WO1997000947A1 (fr) 1995-06-23 1996-06-20 Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
NO975953D0 NO975953D0 (no) 1997-12-18
NO975953L true NO975953L (no) 1997-12-18

Family

ID=9480335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975953A NO975953L (no) 1995-06-23 1997-12-18 Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene

Country Status (16)

Country Link
US (3) US6420170B1 (cs)
EP (1) EP0833896A1 (cs)
JP (1) JP3821846B2 (cs)
KR (1) KR100514070B1 (cs)
AU (1) AU716508B2 (cs)
BR (1) BR9608965A (cs)
CA (1) CA2222270A1 (cs)
CZ (1) CZ295934B6 (cs)
FR (1) FR2735789B1 (cs)
HU (1) HU224679B1 (cs)
IL (2) IL122710A0 (cs)
MX (1) MX9709549A (cs)
NO (1) NO975953L (cs)
SK (1) SK174297A3 (cs)
WO (1) WO1997000947A1 (cs)
ZA (1) ZA965306B (cs)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
FR2737222B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems
EP0931158A1 (en) * 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP0859008A3 (en) * 1997-02-18 2000-04-05 Hoechst Aktiengesellschaft Nucleic acid construct for the cell cycle regulated expression of structural genes
EP0860445A1 (en) * 1997-02-18 1998-08-26 Hoechst Aktiengesellschaft New nucleotide sequences for the cell cycle regulated expression of structural genes
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO2000016799A1 (en) 1998-09-23 2000-03-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating chronic pain
NZ511798A (en) * 1998-10-19 2004-01-30 Powderject Vaccines Inc Minimal promoters comprising a promoter not linked to its native enhancer and such minimal promoters linked to an antigen
CN1074459C (zh) * 1998-11-25 2001-11-07 马丁 重组腺病毒－胸苷激酶构建体及其获得方法和用途
EP1083230A1 (en) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US7115391B1 (en) * 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US7109029B2 (en) * 2001-02-23 2006-09-19 Cell Genesys, Inc. Vector constructs
KR100432953B1 (ko) * 2001-09-01 2004-05-28 김주항 개선된 종양 살상 효과를 나타내는 재조합 아데노바이러스
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
CA2369985A1 (en) * 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
KR100697245B1 (ko) * 2005-03-28 2007-03-21 한국생명공학연구원 중금속 유도성 프로모터와 이의 생물공학적 활용
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
NZ751966A (en) 2016-09-20 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh New promoters
CA3036310A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
WO2018057441A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
MX2019003161A (es) 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de insercion orf70 de ehv.
WO2018075978A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
EP3596116B1 (en) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
BR112020007542A2 (pt) 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
EA202000353A1 (ru) 2018-06-04 2022-01-14 Калиди Биотерапьютикс, Инк. Основанные на клетках носители для потенциализации вирусной терапии
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3116192C (en) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2022524951A (ja) 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
AU2021258194A1 (en) 2020-04-22 2022-11-24 Indapta Therapeutics, Inc. Natural killer (NK) cell compositions and methods for generating same
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
US20230203535A1 (en) * 2020-05-26 2023-06-29 St. Jude Children's Research Hospital, Inc. Recombinant P5 Promoter for Use in Reducing DNA Contamination of AAV Preparations
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager
WO2023182476A1 (ja) * 2022-03-25 2023-09-28 学校法人自治医科大学 アデノ随伴ウイルス（ａａｖ）ベクターの効率の良い産生システム

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1024198A3 (en) * 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5814618A (en) * 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6110744A (en) * 1996-11-13 2000-08-29 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement

Also Published As

Publication number Publication date
SK174297A3 (en) 1998-09-09
WO1997000947A1 (fr) 1997-01-09
HUP9900050A3 (en) 2001-08-28
EP0833896A1 (fr) 1998-04-08
CZ295934B6 (cs) 2005-12-14
FR2735789B1 (fr) 1997-07-25
HUP9900050A1 (hu) 1999-04-28
US20030039634A1 (en) 2003-02-27
NO975953D0 (no) 1997-12-18
US6420170B1 (en) 2002-07-16
CZ413097A3 (cs) 1998-03-18
IL122710A (en) 2006-10-05
HU224679B1 (hu) 2005-12-28
FR2735789A1 (fr) 1996-12-27
KR100514070B1 (ko) 2005-12-21
KR19990028307A (ko) 1999-04-15
BR9608965A (pt) 1999-06-29
CA2222270A1 (fr) 1997-01-09
US20020098165A1 (en) 2002-07-25
AU716508B2 (en) 2000-02-24
JPH11507835A (ja) 1999-07-13
JP3821846B2 (ja) 2006-09-13
US7033826B2 (en) 2006-04-25
IL122710A0 (en) 1998-08-16
ZA965306B (en) 1997-01-24
AU6363996A (en) 1997-01-22
MX9709549A (es) 1998-03-31

Similar Documents

Publication Publication Date Title
NO975953D0 (no) Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene
IL122347A0 (en) Recombinant adenovirus and adeno-associated virus cell lines methods of production and pharmaceutical compositions containing the same
GB9515711D0 (en) Cosmetic formulations having keratolytic and/or anti-acne activity,their preparations and use
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
AU5588298A (en) Adeno-associated viral vector-mediated delivery of dna to cells of the liver
FI961037A7 (fi) Valmisteet osteogenisten proteiinien antamiseksi
FI102132B1 (fi) ATM-solun otsikkokenttien käyttö radiovälitteisessä ATM-tiedonsiirrossa
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
AU3171997A (en) Cosmetic and/or pharmaceutical preparations
NO307510B1 (no) Bicykliske aromatiske forbindelser, deres anvendelse og farmasøytiske og kosmetiske preparater derav
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
NO20016247L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende derivatene
NO942910L (no) Nye baccatin-III- og 10-desacetyl-baccatin-III-derivater, deres fremstillinger, samt farmasöytiske preparater inneholdende derivatene
IL113484A0 (en) Viral proteins pharmaceutical compositions containing them their preparation and use
MA26434A1 (fr) Composes n-alkylfuranne-nitrone et leur utilisation en tant q'agents pharmaceutiques
NO308251B1 (no) Karbohydratderivater, farmasøytisk blanding inneholdende karbohydratderivater samt anvendelse av samme
DK439589D0 (da) Fluorsubstituerede 4'-demethylepipodophyllotoksinderivater samt farmaceutiske praeparater indeholdende samme
AU2408397A (en) Ob protein receptor genes and use of the same
IT9020072A0 (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
DK597784A (da) Silanmodificerede esterblandinger, fremgangsmaader til deres fremstilling samt deres anvendelse i farmaceutiske og kosmetiske praeparater
NO993125L (no) Steroider substituert i posisjon 11, fremgangsmåte for fremstilling av disse, deres anvendelse som medisiner samt farmasöytiske preparater inneholdende disse
NO965370L (no) Substituerte kromanylsulfonyl(tio)ureaer, fremgangsmåter til deres fremstilling, deres anvendelse i farmasöytiske preparater samt farmasöytiske preparater inneholdende forbindelsene
NO20020404L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende derivatene
王保树 Difficulties in the Corporatization of State-owned Enterprises and Legal Considerations
NO965504D0 (no) Nye anti-tumor- og anti-leukemistoffer, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application